Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Investor Presentation (July 2024)
42 slides from Chimeric Therapeutics's investor presentation, Jul 25, 2024
Slide 1: Pioneers in Cell Therapy: Investor Update July 2024
For personal use only CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Investor Update | July 2024 ASX: CHM 20 24 CHIMERICTHERAPEUTICS.COM
Slide 2: Disclaimer
JULY 2024 | 2 DISCLAIMER For personal use only Certain statements contained in this presentation, applicable regulatory authorities may ask for additional including, without limitation, statements containing the data, information or studies to be completed or provided words “believes,” “plans,” “exp
Slide 3: CHM is a cancer cell therapy company
JULY 2024 | 3 For personal use only ASX:CHM CHIMERIC THERAPEUTICS CHM is a cancer cell therapy company with 3 CAR T & NK assets in 4 Phase 1/1b trials 20 24 CHIMERICTHERAPEUTICS.COM
Slide 4: Investment Highlights and Corporate Profile
JULY 2024 | 4 INVESTMENT HIGHLIGHTS 4 4 phase 1/1b clinical trials CORPORATE PROFILE For personal use only under 3 FDA INDs at 4 leading US centres Multiple clinical updates Exchange ASX:CHM CHIMERIC THERAPEUTICS in the next 12mths Share Price $0.02 Experienced leadership team in cell therapy clinic
Slide 5: CAR-T Cell Therapy Explained
JULY 2024 | 5 CAR-T CELL THERAPY EXPLAINED Use a patients own blood cells to make their individualised cancer therapy For personal use only CHIMERIC THERAPEUTICS Laboratory Individual therapy engineering manufactured Leukapheresis (blood draw) Infusion into from individual patient individual patient
Slide 6: CHM: Broad Portfolio
JULY 2024 | 6 CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials For personal use only CHM CDH17 CHM CLTX CHM CORE-NK CHIMERIC THERAPEUTICS CAR-T CAR-T ‘OFF THE SHELF’ NK Technology from: Technology from: Technology from: Phase 1 completed: COH PHASE 1B PHASE 1B PHASE 1/2 TRIAL OPEN PHAS
Slide 7: The Only CDH17 CAR-T Globally in Clinical Trials
JULY 2024 | 7 For personal use only THE ONLY CDH17 CHIMERIC THERAPEUTICS CAR-T GLOBALLY CDH17 IN CLINICAL TRIALS 20 24 CHIMERICTHERAPEUTICS.COM
Slide 8: CDH17 Overview
JULY 2024 | 8 CDH17 OVERVIEW CDH17 is protein on the surface of Gastrointestinal cancers (green on For personal use only purple cells in picture) Compelling pre-clinical efficacy in CHIMERIC THERAPEUTICS Gastric, Pancreatic and Dr. Xianxin Neuroendocrine cancers Hua, M.D., Ph.D. Dr. Carl June M.D. P
Slide 9: Intense Scientific Interest in CDH17
JULY 2024 | 9 INTENSE SCIENTIFIC INTEREST IN CDH17 200+ PUBLICATIONS IN PAST 2 YEARS For personal use only CHIMERIC THERAPEUTICS ‘24 ‘24 ‘24 ‘24 ‘24 ‘24 ‘23 ‘23 Biomater Res. Molecular & Cellular Proteomics Cancer Res. Cancer Res. Cancer Cell Int. J Exp Clin Cancer Res. Lung. Front. Pharmacol. 2024
Slide 10: CHM CDH17 is the First CDH17 Targeting CAR-T in Clinical Trials
JULY 2024 | 10 CHM CDH17 IS THE FIRST CDH17 TARGETING CAR-T IN CLINICAL TRIALS For personal use only COMPANY CHIMERIC THERAPEUTICS ASSET CHM-CDH171 Cabomatig2,8 TORL-3-6003,6 BI 9057114,5,7 PHASE Phase 1/2 Phase 1 Phase 1 Phase 1 MODE CAR-T Antibody Antibody Antibody Solid tumors Solid tumors Solid
Slide 11: CHM CDH17 CAR-T Phase Recruiting
JULY 2024 | 11 CHM CDH17 CAR-T PHASE 1 RECRUITING The first CDH17 CAR T cell therapy in clinical trials in the world. For personal use only CHM CDH17 PERSONALISED CAR-T: AUTOLOGOUS CHIMERIC THERAPEUTICS CAR-T First in class CDH17 CAR T for gastrointestinal cancers Technology from: FDA IND clearance:
Slide 12: Encouraging Pre-Clinical Results
JULY 2024 | 12 ENCOURAGING PRE-CLINICAL RESULTS CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models For personal use only NEUROENDOCRINE TUMOURS GASTRIC CANCER CHIMERIC THERAPEUTICS PANCREATIC CANCER CHM CDH17 CAR-T 20 24 CHIMERICTHERAPEUTICS.COM
Slide 13: CHM CDH17 Clinical Development Strategy
JULY 2024 | 13 CHM CDH17 CLINICAL DEVELOPMENT STRATEGY FDA IND approved phase 1/2 | Clinicaltrials.gov Identifier NCT 06055439 For personal use only JUNE ‘25 CHIMERIC THERAPEUTICS PHASE 1 PHASE 2 EFFICACY REGISTRATION SAFETY N=15 N=70 MARKET UPDATE 3/3 + 5/5 Partner or License to Big Pharma CHM CDH1
Slide 14: CHM CDH17 Total Global Market Size
JULY 2024 | 14 CHM CDH17 TOTAL GLOBAL MARKET SIZE For personal use only Pancreatic Gastric Cancer Cancer CHIMERIC THERAPEUTICS $25.3B in 2023 Bowel Neuroendocrine Cancer Cancer CHM CDH17 CAR-T 20 https://www.grandviewresearch.com/industry-analysis/ pancreatic-cancer-treatment-market 24 https://www.g
Slide 15: CLTX
JULY 2024 | 15 For personal use only CHIMERIC THERAPEUTICS CLTX 20 24 CHIMERICTHERAPEUTICS.COM
Slide 16: Chlorotoxin (CLTX) CAR T Overview
JULY 2024 | 16 CHLOROTOXIN (CLTX) CAR T OVERVIEW Designed by the team at City of Hope to target glioblastoma, one of the For personal use only most lethal types of brain cancer. CHIMERIC THERAPEUTICS Uniquely uses Chlorotoxin, a peptide derived from deathstalker scorpion venom to target brain cancer
Slide 17: CHM CLTX CAR-T Phase 1B Trial Open
JULY 2024 | 17 CHM CDH17 CAR-T PHASE 1 RECRUITING The first CLTX CAR T cell therapy in development in the world For personal use only CHM CLTX PERSONALISED CAR-T: AUTOLOGOUS CHIMERIC THERAPEUTICS CAR-T First in class CLTX CAR T for brain cancer and solid tumours Technology from: Preliminary Positive
Slide 18: CHM CLTX Clinical Development Strategy
JULY 2024 | 18 CHM CLTX CLINICAL DEVELOPMENT STRATEGY FDA IND approved phase 1B For personal use only CHIMERIC THERAPEUTICS PHASE 1A PHASE 2 PHASE 1B EFFICACY REGISTRATION SAFETY N=XX N=1+11 N=70 COMPLETED IND Partner or sale to Amendment Big Pharma CHM CLTX CHM 1101 20 24 CHIMERICTHERAPEUTICS.COM
Slide 19: CHM CLTX Total Global Market Size
JULY 2024 | 19 CHM CLTX CHM 1101 TOTAL GLOBAL MARKET SIZE For personal use only Glioblastoma CHIMERIC THERAPEUTICS $2.5B in 2023 CHM CLTX CHM 1101 20 24 https://www.grandviewresearch.com/industry-analysis/ glioblastoma-multiforme-treatment-gbm-market CHIMERICTHERAPEUTICS.COM
Slide 20: Off the Shelf Core (Allo) NK
JULY 2024 | 20 For personal use only CHIMERIC THERAPEUTICS OFF THE CORE SHELF (ALLO) NK 20 24 CHIMERICTHERAPEUTICS.COM
Slide 21: NK Cell Therapy Overview
JULY 2024 | 21 NK CELL THERAPY OVERVIEW Natural killer cells (NK) are white blood cells that can destroy cancer cells and For personal use only other infections in the body & are a critical part of the immune system • Can identify and kill cancer cells CHIMERIC THERAPEUTICS • Low risk of safety conc
Slide 22: CHM CORE-NK Phase Recruiting
JULY 2024 | 22 CHM CORE-NK PHASE 1 RECRUITING Two Phase 1 trials recruiting For personal use only CHM CORE-NK CORE-NK: ALLOGENEIC CHIMERIC THERAPEUTICS ‘OFF THE SHELF’ NK Source of cells: Universal Healthy Donor Technology from: Positive Phase 1A Clinical Trial completed at Case Western Two ongoing
Slide 23: CHM CORE NK Phase Study Results
JULY 2024 | 23 CHM CORE NK PHASE 1 STUDY RESULTS Ongoing Complete response COMPLETE For personal use only PATIENT #8 RESPONSE 33-year-old female CORE NK INFUSION CHIMERIC THERAPEUTICS DAY 100 DIAGNOSIS: Ovarian cancer DAY 0, 14 HISTORY: Progressive disease with prior allogeneic transplant SAFETY: No
Slide 24: AML Phase 1B Clinical Trial Open
JULY 2024 | 24 AML PHASE 1B CLINICAL TRIAL OPEN CHM CORE-NK + AZA + VEN in front-line AML Clinical Trials.gov Identifier: NCT05834244 For personal use only CHIMERIC THERAPEUTICS CORE NK FDA REGISTERED FDA REGISTERED CELLS CHEMOTHERAPY BLOOD CANCER DRUG 20 CHM CORE NK ‘OFF THE SHELF’ NK 24 CHIMERICTH
Slide 25: CRC Phase 1B Clinical Trial Open
JULY 2024 | 25 CRC PHASE 1B CLINICAL TRIAL OPEN WORLD FIRST TRIAL OF NK CELLS WITH VACTOSERTIB IN BOWEL CANCER CLINICAL TRIALS.GOV IDENTIFIER: NCT05400122 For personal use only CHIMERIC THERAPEUTICS Building upon the efficacy signal in the phase 1A CORE NK clinical trial, this trial aims to improve
Slide 26: CHM CORE-NK Clinical Development Strategy
JULY 2024 | 26 CHM CORE-NK CLINICAL DEVELOPMENT STRATEGY X 2 FDA IND approved phase 1B For personal use only CHIMERIC THERAPEUTICS PHASE 1A PHASE 2 PHASE 1B EFFICACY REGISTRATION SAFETY COMPLETED N=20 N= 80 Partner or License to Big Pharma CHM CORE NK ‘OFF THE SHELF’ NK 20 24 CHIMERICTHERAPEUTICS.CO
Slide 27: Multiple Value Realisation Pathways
JULY 2024 | 27 MULTIPLE VALUE REALISATION PATHWAYS For personal use only CHIMERIC THERAPEUTICS Sale of the Develop Company Independently Strategic 20 24 Partnership with Big Pharma CHIMERICTHERAPEUTICS.COM
Slide 28: Multiple Clinical Catalysts in the Next 12 Months
JULY 2024 | 28 MULTIPLE CLINICAL CATALYSTS IN THE NEXT 12MTHS 2023 Achievements and Deliverables in 2024 2023 Achievements 2024 Deliverables For personal use only ✓ Ph. 1/2 Site Open CHM CDH17 ✓ FDA IND Clearance for Ph. 1/2 Trial • 1st patient dosed CHIMERIC THERAPEUTICS CHM 2101 • Ph. 1 Preliminar
Slide 29: Investment Highlights and Corporate Profile
JULY 2024 | 30 INVESTMENT HIGHLIGHTS 4 4 phase 1/1b clinical trials CORPORATE PROFILE For personal use only under 3 FDA INDs at 4 leading US centres Multiple clinical updates Exchange ASX:CHM CHIMERIC THERAPEUTICS in the next 12mths Share Price $0.02 Experienced leadership team in cell therapy clini
Slide 30: Appendix
JULY 2024 | 31 For personal use only CHIMERIC THERAPEUTICS APPENDIX 20 24 CHIMERICTHERAPEUTICS.COM
Slide 31: CHM Leadership Team
JULY 2024 | 32 CHM LEADERSHIP TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION For personal use only CHIMERIC THERAPEUTICS Dr Rebecca McQUALTER Dr Jason LITTEN Dr Stephanie ASTROW Kelly THORNBURG Chief Operating Officer Chief Medical Officer VP Translational Sciences VP Manufacturing 75+
Slide 32: What is Cell Therapy?
JULY 2024 | 33 WHAT IS CELL THERAPY? Cell therapy is the transfer of live cells into a patient to help lessen For personal use only or cure a disease. In its most basic form is a blood transfusion. Today’s cell therapies can involve the engineering of live cells to attack specific diseases CHIMERIC
Slide 33: Alternative Cell Types: T Cells vs NK Cells
JULY 2024 | 34 WHAT IS CELL THERAPY? ALTERNATIVE CELL TYPES: T CELLS VS. NK CELLS For personal use only T CELLS NK CELLS CHIMERIC THERAPEUTICS T cells are part of the adaptive immune Natural Killer (NK) cells are part of the innate system- primed to recognise a specific threat immune response – resp
Slide 34: CHM CDH17 CAR T Phase 1/2 Clinical Trial in GI Cancers
JULY 2024 | 35 CHM CDH17 CAR T PHASE 1/2 CLINICAL TRIAL IN GI CANCERS For personal use only COLORECTAL CHM 450 X 106 CANCER OBJECTIVES: Characterise the safety CDH17 CHM 2101 CHIMERIC THERAPEUTICS and tolerability of CDH17 CAR and NETs determine the G1, G2, and well- differentiated G3 Tumor Tumor re
Slide 35: CHM CDH17 CAR T Target Competitors in Detail
JULY 2024 | 36 CHM CDH17 CAR T TARGET COMPETITORS IN DETAIL For personal use only Preclinical Phase 1 CHM CDH17 CAR T CHM CDH17 CDH17 CAR NK CHM CDH17 CDH17 CAR T CDH17 Ospedale San Raffaele CHM 2101 CHIMERIC THERAPEUTICS Chimeric Therapeutics Chimeric Therapeutics ARB011 ARB001 Cell CDH17 NK/T CDH1
Slide 36: CHM CLTX CAR T Advancing Development to Phase 1B
JULY 2024 | 37 CHM CLTX CAR T ADVANCING DEVELOPMENT TO PHASE 1B CLINICAL TRIALS.GOV IDENTIFIER: NCT05627323 For personal use only CHM CLTX SAFETY & EFFICACY ASSESSMENT PART A PART B CHM 1101 CHIMERIC THERAPEUTICS OBJECTIVES: DOSE CONFIRMATION DOSE EXPANSION • PFS, OS, ORR • Safety & Feasibility • RP
Slide 37: Positive Preliminary Phase 1A Clinical Data in Brain Cancer
JULY 2024 | 38 POSITIVE PRELIMINARY PHASE 1A CLINICAL DATA IN BRAIN CANCER (GLIOBLASTOMA) For personal use only DISEASE CHM SURVIVAL CONTROL RATE CLTX CHM 1101 CHIMERIC THERAPEUTICS ~10 months 55% Median survival in patients that achieved disease control Disease Control Rate (DCR) in heavily pretrea
Slide 38: CHM CLTX Phase 1B Improved Design
JULY 2024 | 39 CHM CLTX PHASE 1B IMPROVED DESIGN PROPOSED CLINICAL DESIGN: ADDITION OF SYSTEMIC DELIVERY AND CHEMOTHERAPY CLINICAL TRIALS.GOV IDENTIFIER: NCT05627323 For personal use only CHM Enroll and apheresis Debulking (if needed), research 1st dose (Systemic) CLTX 2nd dose - Local CHM 1101 CHIM
Slide 39: ADVENT-AML Phase 1B Clinical Trial
JULY 2024 | 40 ADVENT-AML PHASE 1B CLINICAL TRIAL CHM CORE-NK 0201 + AZA + VEN IN FRONT-LINE AML For personal use only Despite treatment advances, outcomes for AML patients not eligible HIGH UNMET NEED IN AML for intensive chemotherapy or allogeneic stem cell transplant are CHM poor CORE-NK CHM 0201
Slide 40: CHM CORE-NK 0201 + Vactosertib
JULY 2024 | 41 CHM CORE-NK 0201 + VACTOSERTIB FDA APPROVED FIRST EVER TRIAL OF NK CELLS WITH VACTOSERTIB For personal use only CHM A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal CORE-NK Donor NK Cells in Combination With IL-2 and TGF-beta Receptor I Inhibitor Vacto
Slide 41: CHM CORE-NK Development Plan
JULY 2024 | 42 CHM CORE-NK DEVELOPMENT PLAN THE FUTURE For personal use only CHM 0201 COMBINATIONS 1 Exploring novel combinations utilising NK cells with CHM CORE-NK standard of care therapies CHM 0201 CHIMERIC THERAPEUTICS 2 CHM 0301 NEXT GENERATION PLATFORM CORE Next generation armoured platform d
Slide 42: Pioneers in Cell Therapy: Contact
JULY 2024 | 43 For personal use only CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Dr Rebecca McQualter Chief Operating Officer ASX: Chimeric Therapeutics Ltd Melbourne, Australia CHM Tel: +61 498 966 180 investor@chimerictherapeutics.com 20 24 CHIMERICTHERAPEUTICS.COM
Chimeric Therapeutics — Investor Presentation (July 2024) on 6ix